City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  55  Clinical trial(s) found  (Page 1 of 3 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for Brain and Nervous System Cancer:
COH Protocol Number: 16190 ClinicalTrials.gov Number: NCT02402244

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG APEC14B1: The Project: Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

COH Protocol Number: 16064 ClinicalTrials.gov Number: NCT03389230

Principal Investigator: Behnam Badie, MD
Sponsor: Institutional

Title:  Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a HER2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients with Recurrent/Refractory Malignant Glioma

COH Protocol Number: 14221 ClinicalTrials.gov Number: NCT02176967

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

COH Protocol Number: 14108 ClinicalTrials.gov Number: NCT02192359

Principal Investigator: Jana Portnow, MD
Sponsor: NCI Approved External Peer Review

Title:  A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas

COH Protocol Number: 13384 ClinicalTrials.gov Number: NCT02208362

Principal Investigator: Behnam Badie, MD
Sponsor: NCI Approved External Peer Review

Title:  Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Ra2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients with Recurrent/Refractory Malignant Glioma

COH Protocol Number: 13140 ClinicalTrials.gov Number: NCT01096368

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG ACNS0831:Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma ages 1-21 years

COH Protocol Number: 08138

Principal Investigator: Ellie Maghami, MD
Sponsor: Institutional

Title:  City of Hope Head and Neck Database Using the American Head and Neck Society Otobase

The following studies are available for many cancer types, including Brain and Nervous System Cancer:
COH Protocol Number: 18116 ClinicalTrials.gov Number: NCT03410927

Principal Investigator: Sumanta Pal, MD
Sponsor: Industrial

Title:  A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of TAS0728, an Oral Covalent Binding Inhibitor of HER2, in Subjects with Advanced Solid Tumors with HER2 or HER3 Abnormalities

COH Protocol Number: 18056 ClinicalTrials.gov Number: NCT03406949

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory B7-H3-Expressing Tumors

COH Protocol Number: 18029 ClinicalTrials.gov Number: NCT03556228

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma

COH Protocol Number: 17491

Principal Investigator: Saro Armenian, DO
Sponsor: Institutional

Title:  Multi-Institutional Pilot Study to Assess the Needs of Childhood Cancer Survivors (CCS) Followed in Long-term Survivorship Clinics

COH Protocol Number: 17422

Principal Investigator: Jeannine Mccune, PharmD
Sponsor: Institutional

Title:  Feasibility of Longitudinal Blood Sample Collection in Patients Receiving Post Transplant Cyclophosphamide

COH Protocol Number: 17345 ClinicalTrials.gov Number: NCT03199586

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  First-in-Human, Dose Finding, Open Label Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients with Advanced or Metastatic Solid Tumors (including Lymphoma)

COH Protocol Number: 17332 ClinicalTrials.gov Number: NCT03355066

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects with Advanced Solid Tumors

COH Protocol Number: 17314

Principal Investigator: Arti Hurria, MD
Sponsor: Cooperative Group

Title:  Alliance A171603: Feasibility of an Electronic Geriatric Assessment (eGA) for Older Adults With Cancer

COH Protocol Number: 17210 ClinicalTrials.gov Number: NCT02964013

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

COH Protocol Number: 17154

Principal Investigator: Jeannine Mccune, PharmD
Sponsor: NCI Approved External Peer Review

Title:  Blood Samples to Identify Biomarkers for Busulfan

COH Protocol Number: 17150 ClinicalTrials.gov Number: NCT03170960

Principal Investigator: Sumanta Pal, MD
Sponsor: Industrial

Title:  A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

COH Protocol Number: 17144 ClinicalTrials.gov Number: NCT02723955

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination with Anticancer Agents in Subjects with Selected Advanced Solid Tumors

COH Protocol Number: 17109 ClinicalTrials.gov Number: NCT03104699

Principal Investigator: Edward Wang, MD
Sponsor: Industrial

Title:  A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer

COH Protocol Number: 17084 ClinicalTrials.gov Number: NCT02052778

Principal Investigator: Daneng Li, MD
Sponsor: Industrial

Title:  A Dose-Finding Phase 1 Study of TAS-120 in Patients With Advanced Solid Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities Followed By a Phase 2 Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities

COH Protocol Number: 16334

Principal Investigator: Saro Armenian, DO
Sponsor: Institutional

Title:  Assessment of Cardiovascular Reserve Capacity in Hematopoietic Cell Transplantation Survivors

COH Protocol Number: 16273 ClinicalTrials.gov Number: NCT02890368

Principal Investigator: Christiane Querfeld, MD, PhD
Sponsor: Industrial

Title:  A Phase I Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides

COH Protocol Number: 16251 ClinicalTrials.gov Number: NCT03067766

Principal Investigator: Jaroslava Salman, MD
Sponsor: Institutional

Title:  A Pilot Study to Test the Feasibility of Comic Art Creation for Symptom Management in Cancer Supportive Care

COH Protocol Number: 16219

Principal Investigator: Jeffrey Weitzel, MD
Sponsor: NCI Approved External Peer Review

Title:  Understanding How Clients Make Meaning of Their Variants of Uncertain Significance in the Age of Multi-Gene Panel Testing for Cancer Susceptibility

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.